Dr. Lin Yu's practice focuses on U.S. and foreign patent prosecution and patent portfolio management in the areas of biotechnology, chemistry, and pharmaceuticals. He also assists attorneys in advising established and emerging pharmaceutical and biotechnology companies on the strategic planning and acquisition of intellectual property portfolios. His experiences include patent portfolio evaluations and due diligence investigations, including patentability, invalidity, infringement, and freedom-to-operate investigations. Representative clients include Ambit Biosciences, Axikin Pharmaceuticals, BioMarin Pharmaceutical, Celgene Corporation, Idenix Pharmaceuticals, and Puma Biotechnology.
Before joining Jones Day in 2007, Lin co-founded Triad Therapeutics, served as vice president of chemistry and biochemistry, and oversaw the development of its small molecule kinase inhibitors for rheumatoid arthritis, which was later licensed to Novartis. Lin also served as a group leader at La Jolla Pharmaceutical Company, where he led the development of its first clinical candidate, and was a two-time recipient of the company's President's Award in recognition of his discovery, innovation, and productivity.
Over the course of his professional career, Lin has gained extensive experience in a variety of drug discovery technologies, including structure-based drug design, high-throughput chemistry, high-throughput screening, disease animal models, and drug delivery.